Background. High levels of intercellular adhesion molecule-1 (ICAM-1) have been reported both on hepatocytes and in serum of patients with chronic liver diseases. During interferon therapy, a reduction of intrahepatic expression of ICAM-1 has been shown. Little is known about the effect of this drug on ICAM-1 serum levels (sICAM-1). Methods. We evaluated sICAM-1 levels before, during and after interferon treatment in 22 patients with type C chronic hepatitis or cirrhosis. We also studied nine healthy subjects as control group. Results. Statistically significant higher levels of sICAM-1 were shown in patients with liver disease compared to the controls. The ICAM-1 baseline levels were similar in patients with chronic hepatitis or cirrhosis but, during therapy, the sICAM-1 level significantly decreased only in patients with chronic hepatitis. After withdrawal of interferon sICAM-1 levels rebounded to initial values. Conclusions. In our study IFN therapy seemed to be able to determine a transient reduction of sICAM levels that disappeared after drug suspension.
|Number of pages||4|
|Journal||European Journal of Laboratory Medicine|
|Publication status||Published - 1997|
ASJC Scopus subject areas